AI Analysis
AI-generated analysis. Always verify with the original filing.
Matinas BioPharma Holdings, Inc. received a NYSE American non-compliance notice on April 2, 2026, for failing to meet minimum stockholders’ equity requirements under Sections 1003(a)(i)–(iii) of the Company Guide, with $4.83 million equity as of December 31, 2025, and losses in each of the past five fiscal years.
Key Takeaways
1The Company has $4.83 million in stockholders’ equity as of December 31, 2025 — below the $6.0 million threshold required for five consecutive years of losses under NYSE American Section 1003(a)(iii).
2The NYSE American granted until May 2, 2026, to submit a compliance plan; if accepted, the Company may have up to 18 months to regain compliance.
3Delisting proceedings will commence if the compliance plan is rejected, though current trading on NYSE American continues uninterrupted pending resolution.
4The independent auditor’s report on the 2025 Form 10-K includes a going-concern explanatory paragraph, reinforcing financial vulnerability signaled by the listing deficiency.
5The Notice does not impact ongoing business operations or SEC reporting obligations, per the filing.